Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N J Dibb

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Leukemia|February 12, 2010
Lck is a key target of imatinib and dasatinib in T-cell activationK C Lee, I Ouwehand, A L Giannini, et al.
Journal of Molecular Biology|June 25, 1985
Sequence analysis of mutations that affect the synthesis, assembly and enzymatic activity of the unc-54 myosin heavy chain of Caenorhabditis elegansN J Dibb, D M Brown, J Karn, et al.
Leukemia|September 14, 2007
Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesisN Brownlow, A E Russell, H Saravanapavan, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Leukemia|February 12, 2010
Lck is a key target of imatinib and dasatinib in T-cell activationK C Lee, I Ouwehand, A L Giannini, et al.
Journal of Molecular Biology|June 25, 1985
Sequence analysis of mutations that affect the synthesis, assembly and enzymatic activity of the unc-54 myosin heavy chain of Caenorhabditis elegansN J Dibb, D M Brown, J Karn, et al.
Leukemia|September 14, 2007
Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesisN Brownlow, A E Russell, H Saravanapavan, et al.
Pageof 3